 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Keytruda (pembrolizumab) / Merck (MSD), MK-1484 / Merck (MSD)
Enrollment closed, Monotherapy, Metastases: A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) (clinicaltrials.gov) - Aug 25, 2024
P1, N=70, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD), MK-1484 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) (clinicaltrials.gov) - Mar 2, 2023
P1, N=70, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
- ||| Keytruda (pembrolizumab) / Merck (MSD), MK-1484 / Merck (MSD)
Enrollment open, Monotherapy, Metastases: A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) (clinicaltrials.gov) - Jun 27, 2022
P1, N=70, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026 Not yet recruiting --> Recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD), MK-1484 / Merck (MSD)
New P1 trial, Monotherapy, Metastases: A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) (clinicaltrials.gov) - May 18, 2022
P1, N=70, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC